At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 68 enrolled
Drug / intervention
Pevonedistat +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Pevonedistat, Docetaxel, and 2 other interventions for Advanced Solid Neoplasm. Completed, enrolled 68 participants across 8 sites.
Detailed Summary
The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m\^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Neoplasm
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionJan 2019
Study CompletionJun 2021
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartNov 15, 2017
Primary CompletionJan 7, 2019
Study CompletionJun 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.7 years ago
Interventions
Pevonedistatdrug
Pevonedistat intravenous infusion.
Docetaxeldrug
Docetaxel intravenous infusion.
Carboplatindrug
Carboplatin intravenous infusion.
Paclitaxeldrug
Paclitaxel intravenous infusion.